Concepts (282)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastrointestinal Hemorrhage | 32 | 2024 | 237 | 14.440 |
Why?
|
| Colonoscopy | 14 | 2023 | 281 | 4.480 |
Why?
|
| Anticoagulants | 11 | 2022 | 428 | 3.600 |
Why?
|
| Hospitalization | 11 | 2022 | 883 | 3.000 |
Why?
|
| Patient Discharge | 7 | 2024 | 324 | 2.110 |
Why?
|
| Hemostasis, Endoscopic | 3 | 2018 | 16 | 1.820 |
Why?
|
| Esophageal Diseases | 3 | 2015 | 27 | 1.500 |
Why?
|
| Warfarin | 3 | 2020 | 104 | 1.390 |
Why?
|
| Risk Assessment | 8 | 2019 | 2315 | 1.150 |
Why?
|
| Liver Cirrhosis | 4 | 2018 | 257 | 1.130 |
Why?
|
| Colonic Polyps | 4 | 2023 | 132 | 1.120 |
Why?
|
| Esophageal Neoplasms | 4 | 2018 | 330 | 1.070 |
Why?
|
| Humans | 64 | 2025 | 89785 | 1.050 |
Why?
|
| Fibrinolytic Agents | 2 | 2018 | 225 | 1.040 |
Why?
|
| Esophageal Stenosis | 2 | 2015 | 26 | 1.000 |
Why?
|
| Eosinophilic Esophagitis | 2 | 2015 | 18 | 0.990 |
Why?
|
| Endoscopy, Digestive System | 2 | 2015 | 69 | 0.980 |
Why?
|
| Patient Readmission | 3 | 2019 | 354 | 0.970 |
Why?
|
| Liver Diseases | 2 | 2017 | 242 | 0.960 |
Why?
|
| Endoscopy, Gastrointestinal | 3 | 2023 | 163 | 0.950 |
Why?
|
| Physicians, Family | 1 | 2024 | 39 | 0.940 |
Why?
|
| Colorectal Neoplasms | 4 | 2022 | 979 | 0.930 |
Why?
|
| Proton Pump Inhibitors | 2 | 2022 | 34 | 0.900 |
Why?
|
| Emergency Service, Hospital | 5 | 2024 | 526 | 0.890 |
Why?
|
| Juniperus | 1 | 2023 | 1 | 0.890 |
Why?
|
| Polyps | 1 | 2023 | 29 | 0.860 |
Why?
|
| Endoscopy | 4 | 2019 | 352 | 0.850 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 1052 | 0.810 |
Why?
|
| Middle Aged | 31 | 2021 | 26080 | 0.810 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2020 | 582 | 0.810 |
Why?
|
| Aged | 26 | 2021 | 19212 | 0.810 |
Why?
|
| Propensity Score | 3 | 2021 | 149 | 0.790 |
Why?
|
| Gastroenterology | 3 | 2023 | 146 | 0.770 |
Why?
|
| Text Messaging | 1 | 2022 | 31 | 0.770 |
Why?
|
| Radiology | 1 | 2024 | 202 | 0.760 |
Why?
|
| Early Diagnosis | 2 | 2018 | 125 | 0.750 |
Why?
|
| Retrospective Studies | 16 | 2024 | 9159 | 0.740 |
Why?
|
| Blood Coagulation Factors | 1 | 2021 | 20 | 0.740 |
Why?
|
| Blood Transfusion | 2 | 2018 | 171 | 0.730 |
Why?
|
| Barrett Esophagus | 3 | 2018 | 94 | 0.730 |
Why?
|
| Vitamin K | 1 | 2021 | 25 | 0.730 |
Why?
|
| Acute Coronary Syndrome | 1 | 2021 | 30 | 0.720 |
Why?
|
| Risk Adjustment | 1 | 2020 | 38 | 0.700 |
Why?
|
| Patient Admission | 2 | 2018 | 114 | 0.700 |
Why?
|
| Recurrence | 7 | 2018 | 1143 | 0.690 |
Why?
|
| Thromboembolism | 2 | 2018 | 119 | 0.690 |
Why?
|
| Angiodysplasia | 1 | 2019 | 4 | 0.680 |
Why?
|
| Machine Learning | 2 | 2019 | 268 | 0.680 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2021 | 146 | 0.670 |
Why?
|
| Spiders | 1 | 2019 | 16 | 0.670 |
Why?
|
| Critical Pathways | 1 | 2019 | 37 | 0.670 |
Why?
|
| Gastrointestinal Agents | 2 | 2022 | 173 | 0.660 |
Why?
|
| Blood Coagulation Disorders | 1 | 2020 | 66 | 0.660 |
Why?
|
| Diverticulum, Colon | 1 | 2018 | 10 | 0.630 |
Why?
|
| Diverticulum | 1 | 2019 | 45 | 0.630 |
Why?
|
| Male | 29 | 2021 | 42582 | 0.620 |
Why?
|
| Severity of Illness Index | 5 | 2019 | 1856 | 0.600 |
Why?
|
| Acute Disease | 4 | 2022 | 844 | 0.590 |
Why?
|
| Female | 29 | 2021 | 46494 | 0.580 |
Why?
|
| Time Factors | 5 | 2018 | 5350 | 0.580 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 159 | 0.580 |
Why?
|
| Cost-Benefit Analysis | 3 | 2016 | 465 | 0.570 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2017 | 19 | 0.570 |
Why?
|
| Colonic Diseases | 1 | 2017 | 61 | 0.550 |
Why?
|
| Alanine Transaminase | 1 | 2016 | 72 | 0.550 |
Why?
|
| Aspartate Aminotransferases | 1 | 2016 | 75 | 0.540 |
Why?
|
| Risk Factors | 8 | 2019 | 5539 | 0.540 |
Why?
|
| Gastroenterologists | 1 | 2017 | 31 | 0.540 |
Why?
|
| Aged, 80 and over | 12 | 2019 | 6778 | 0.540 |
Why?
|
| Patient Care Management | 1 | 2016 | 30 | 0.540 |
Why?
|
| Fellowships and Scholarships | 2 | 2017 | 125 | 0.540 |
Why?
|
| Atrial Fibrillation | 1 | 2020 | 357 | 0.520 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2016 | 175 | 0.520 |
Why?
|
| Stomach Diseases | 1 | 2015 | 19 | 0.510 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2015 | 4 | 0.500 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 319 | 0.500 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 168 | 0.490 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 305 | 0.490 |
Why?
|
| Withholding Treatment | 2 | 2014 | 116 | 0.480 |
Why?
|
| Cryosurgery | 1 | 2015 | 54 | 0.480 |
Why?
|
| Accidental Falls | 1 | 2015 | 48 | 0.480 |
Why?
|
| Cohort Studies | 6 | 2020 | 2886 | 0.480 |
Why?
|
| Intestinal Diseases | 1 | 2015 | 79 | 0.480 |
Why?
|
| Physicians, Primary Care | 1 | 2016 | 105 | 0.470 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 952 | 0.470 |
Why?
|
| Psychotropic Drugs | 1 | 2015 | 79 | 0.470 |
Why?
|
| Hospital Mortality | 1 | 2017 | 403 | 0.460 |
Why?
|
| Multivariate Analysis | 5 | 2020 | 983 | 0.460 |
Why?
|
| Salvage Therapy | 1 | 2015 | 230 | 0.450 |
Why?
|
| Adult | 18 | 2021 | 26767 | 0.430 |
Why?
|
| Stomach Neoplasms | 1 | 2016 | 288 | 0.430 |
Why?
|
| Ischemic Attack, Transient | 1 | 2014 | 182 | 0.430 |
Why?
|
| Coronary Artery Disease | 1 | 2018 | 364 | 0.430 |
Why?
|
| Prospective Studies | 10 | 2021 | 4320 | 0.420 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 401 | 0.420 |
Why?
|
| Prognosis | 6 | 2018 | 3785 | 0.390 |
Why?
|
| Esophagoscopy | 3 | 2018 | 90 | 0.390 |
Why?
|
| Pulmonary Embolism | 1 | 2014 | 229 | 0.390 |
Why?
|
| Wounds and Injuries | 1 | 2015 | 260 | 0.390 |
Why?
|
| Venous Thrombosis | 1 | 2014 | 255 | 0.390 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 1183 | 0.380 |
Why?
|
| Follow-Up Studies | 4 | 2024 | 3663 | 0.370 |
Why?
|
| United States | 8 | 2024 | 7083 | 0.370 |
Why?
|
| Logistic Models | 3 | 2020 | 1214 | 0.360 |
Why?
|
| Chronic Pain | 2 | 2025 | 165 | 0.360 |
Why?
|
| Databases, Factual | 3 | 2019 | 860 | 0.360 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2025 | 840 | 0.350 |
Why?
|
| Glottis | 1 | 2010 | 10 | 0.350 |
Why?
|
| Vocal Cords | 1 | 2010 | 28 | 0.340 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2023 | 332 | 0.340 |
Why?
|
| Carcinoma in Situ | 1 | 2010 | 52 | 0.340 |
Why?
|
| Laryngeal Neoplasms | 1 | 2010 | 89 | 0.330 |
Why?
|
| Catheter Ablation | 3 | 2016 | 254 | 0.320 |
Why?
|
| Dabigatran | 2 | 2020 | 25 | 0.300 |
Why?
|
| Young Adult | 6 | 2020 | 6386 | 0.300 |
Why?
|
| Treatment Outcome | 6 | 2021 | 8243 | 0.300 |
Why?
|
| Administration, Oral | 2 | 2020 | 666 | 0.300 |
Why?
|
| Chickenpox | 1 | 2007 | 38 | 0.290 |
Why?
|
| Herpesvirus 3, Human | 1 | 2007 | 40 | 0.290 |
Why?
|
| Molecular Epidemiology | 1 | 2007 | 54 | 0.290 |
Why?
|
| Cryotherapy | 2 | 2018 | 30 | 0.280 |
Why?
|
| Herpes Zoster | 1 | 2007 | 79 | 0.280 |
Why?
|
| Liver | 3 | 2016 | 1211 | 0.280 |
Why?
|
| Adolescent | 7 | 2021 | 9327 | 0.270 |
Why?
|
| Diagnostic Imaging | 2 | 2023 | 476 | 0.270 |
Why?
|
| Inpatients | 2 | 2022 | 311 | 0.260 |
Why?
|
| Ceruloplasmin | 2 | 2015 | 8 | 0.260 |
Why?
|
| Hepatolenticular Degeneration | 2 | 2015 | 19 | 0.250 |
Why?
|
| Stroke | 1 | 2014 | 990 | 0.250 |
Why?
|
| Elasticity Imaging Techniques | 2 | 2016 | 57 | 0.250 |
Why?
|
| Proportional Hazards Models | 3 | 2018 | 848 | 0.240 |
Why?
|
| Back Pain | 1 | 2025 | 43 | 0.240 |
Why?
|
| Length of Stay | 2 | 2018 | 744 | 0.240 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2015 | 102 | 0.240 |
Why?
|
| Canada | 1 | 2024 | 208 | 0.230 |
Why?
|
| Aftercare | 1 | 2024 | 88 | 0.220 |
Why?
|
| Catheters | 1 | 2024 | 83 | 0.220 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 1 | 2023 | 18 | 0.220 |
Why?
|
| Angiography | 1 | 2024 | 208 | 0.220 |
Why?
|
| Computers | 1 | 2023 | 111 | 0.220 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2024 | 2676 | 0.210 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2010 | 1096 | 0.210 |
Why?
|
| Crohn Disease | 2 | 2021 | 764 | 0.210 |
Why?
|
| Histamine H2 Antagonists | 1 | 2022 | 15 | 0.200 |
Why?
|
| Cathartics | 1 | 2022 | 27 | 0.200 |
Why?
|
| Algorithms | 2 | 2023 | 1904 | 0.200 |
Why?
|
| Remission Induction | 2 | 2021 | 740 | 0.190 |
Why?
|
| Musculoskeletal Pain | 1 | 2021 | 10 | 0.190 |
Why?
|
| Adenoma | 2 | 2021 | 250 | 0.190 |
Why?
|
| Consensus | 1 | 2023 | 365 | 0.190 |
Why?
|
| Capsule Endoscopy | 1 | 2021 | 33 | 0.190 |
Why?
|
| Ticlopidine | 1 | 2021 | 25 | 0.190 |
Why?
|
| Aspirin | 2 | 2022 | 160 | 0.180 |
Why?
|
| Clinical Competence | 2 | 2017 | 794 | 0.180 |
Why?
|
| Ontario | 1 | 2020 | 51 | 0.180 |
Why?
|
| Infant | 4 | 2018 | 3187 | 0.180 |
Why?
|
| Chemoprevention | 1 | 2020 | 92 | 0.170 |
Why?
|
| Child, Preschool | 4 | 2018 | 3765 | 0.170 |
Why?
|
| Blood Coagulation | 1 | 2020 | 91 | 0.170 |
Why?
|
| Artificial Intelligence | 2 | 2021 | 329 | 0.170 |
Why?
|
| Risk | 2 | 2018 | 655 | 0.170 |
Why?
|
| Societies, Medical | 1 | 2023 | 583 | 0.170 |
Why?
|
| Incidence | 3 | 2018 | 1598 | 0.160 |
Why?
|
| Mortality | 1 | 2020 | 149 | 0.160 |
Why?
|
| Triage | 1 | 2019 | 117 | 0.160 |
Why?
|
| Data Warehousing | 1 | 2018 | 4 | 0.160 |
Why?
|
| Lower Gastrointestinal Tract | 1 | 2018 | 8 | 0.160 |
Why?
|
| Age Factors | 3 | 2018 | 1879 | 0.160 |
Why?
|
| Biological Products | 1 | 2021 | 158 | 0.160 |
Why?
|
| Delayed Diagnosis | 1 | 2018 | 34 | 0.150 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2019 | 67 | 0.150 |
Why?
|
| Area Under Curve | 1 | 2018 | 336 | 0.150 |
Why?
|
| Hepatic Encephalopathy | 1 | 2018 | 39 | 0.150 |
Why?
|
| Data Mining | 1 | 2018 | 43 | 0.150 |
Why?
|
| Drug Therapy | 1 | 2018 | 69 | 0.150 |
Why?
|
| Quality Improvement | 1 | 2022 | 457 | 0.150 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 419 | 0.150 |
Why?
|
| Nitrogen | 1 | 2018 | 73 | 0.150 |
Why?
|
| Secondary Prevention | 1 | 2018 | 158 | 0.150 |
Why?
|
| Betacoronavirus | 1 | 2020 | 262 | 0.140 |
Why?
|
| Comorbidity | 2 | 2018 | 952 | 0.140 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 1729 | 0.140 |
Why?
|
| Models, Educational | 1 | 2017 | 49 | 0.140 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2016 | 12 | 0.140 |
Why?
|
| Disease Progression | 2 | 2018 | 1466 | 0.140 |
Why?
|
| Fecal Impaction | 1 | 2016 | 3 | 0.140 |
Why?
|
| Liver Function Tests | 1 | 2016 | 92 | 0.140 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 865 | 0.140 |
Why?
|
| Gastroscopy | 1 | 2016 | 25 | 0.140 |
Why?
|
| Hospital Charges | 1 | 2016 | 29 | 0.140 |
Why?
|
| Odds Ratio | 1 | 2018 | 682 | 0.140 |
Why?
|
| Program Development | 1 | 2017 | 127 | 0.130 |
Why?
|
| Emergencies | 1 | 2017 | 122 | 0.130 |
Why?
|
| Pyridines | 1 | 2018 | 300 | 0.130 |
Why?
|
| Mentors | 1 | 2017 | 89 | 0.130 |
Why?
|
| Medicare | 2 | 2016 | 427 | 0.130 |
Why?
|
| Child | 4 | 2018 | 7233 | 0.130 |
Why?
|
| Hepatitis | 1 | 2015 | 34 | 0.130 |
Why?
|
| Program Evaluation | 1 | 2017 | 312 | 0.130 |
Why?
|
| Medical Order Entry Systems | 1 | 2015 | 27 | 0.120 |
Why?
|
| Medical Overuse | 1 | 2015 | 36 | 0.120 |
Why?
|
| Unnecessary Procedures | 1 | 2015 | 52 | 0.120 |
Why?
|
| beta-Alanine | 1 | 2014 | 6 | 0.120 |
Why?
|
| Rivaroxaban | 1 | 2014 | 12 | 0.120 |
Why?
|
| Enoxaparin | 1 | 2014 | 23 | 0.120 |
Why?
|
| Colonic Pouches | 1 | 2015 | 76 | 0.120 |
Why?
|
| Thiophenes | 1 | 2014 | 43 | 0.120 |
Why?
|
| Benzodiazepines | 1 | 2015 | 69 | 0.120 |
Why?
|
| Nucleosides | 1 | 2014 | 22 | 0.120 |
Why?
|
| Morpholines | 1 | 2014 | 70 | 0.120 |
Why?
|
| Food | 1 | 2015 | 89 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2015 | 216 | 0.120 |
Why?
|
| Treatment Failure | 1 | 2015 | 278 | 0.120 |
Why?
|
| Eosinophils | 1 | 2015 | 194 | 0.120 |
Why?
|
| Pyridones | 1 | 2014 | 56 | 0.120 |
Why?
|
| Constipation | 1 | 2015 | 64 | 0.120 |
Why?
|
| Hepatitis B, Chronic | 1 | 2014 | 32 | 0.120 |
Why?
|
| ROC Curve | 1 | 2017 | 776 | 0.120 |
Why?
|
| Hospital Costs | 1 | 2015 | 109 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 778 | 0.120 |
Why?
|
| Cost of Illness | 1 | 2015 | 148 | 0.120 |
Why?
|
| Nucleotides | 1 | 2014 | 98 | 0.110 |
Why?
|
| Benzimidazoles | 1 | 2014 | 107 | 0.110 |
Why?
|
| Heparin | 1 | 2014 | 185 | 0.110 |
Why?
|
| Anesthesia | 1 | 2016 | 166 | 0.110 |
Why?
|
| Pyrazoles | 1 | 2014 | 150 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2015 | 234 | 0.110 |
Why?
|
| Ischemia | 1 | 2015 | 252 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 2016 | 344 | 0.110 |
Why?
|
| Curriculum | 1 | 2017 | 572 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 539 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 2018 | 0.100 |
Why?
|
| Computer Simulation | 1 | 2016 | 1101 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 654 | 0.100 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 1083 | 0.090 |
Why?
|
| Mass Screening | 1 | 2015 | 645 | 0.090 |
Why?
|
| Colitis, Ulcerative | 1 | 2018 | 750 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2014 | 482 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2765 | 0.090 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2010 | 189 | 0.080 |
Why?
|
| Prevalence | 2 | 2018 | 1249 | 0.080 |
Why?
|
| London | 1 | 2007 | 16 | 0.070 |
Why?
|
| Chickenpox Vaccine | 1 | 2007 | 7 | 0.070 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 2007 | 31 | 0.070 |
Why?
|
| DNA, Viral | 1 | 2007 | 262 | 0.070 |
Why?
|
| Survival Rate | 1 | 2010 | 1890 | 0.060 |
Why?
|
| Injections, Epidural | 1 | 2025 | 7 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 919 | 0.060 |
Why?
|
| Anesthetics, Local | 1 | 2025 | 77 | 0.060 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 2000 | 0.060 |
Why?
|
| Pain Management | 1 | 2025 | 143 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 1350 | 0.050 |
Why?
|
| Iodine | 1 | 2023 | 43 | 0.050 |
Why?
|
| Genotype | 1 | 2007 | 1853 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2022 | 49 | 0.050 |
Why?
|
| Network Meta-Analysis | 1 | 2021 | 6 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2021 | 151 | 0.050 |
Why?
|
| Intestine, Small | 1 | 2023 | 299 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2007 | 2498 | 0.050 |
Why?
|
| Leukocyte L1 Antigen Complex | 1 | 2021 | 47 | 0.050 |
Why?
|
| Ustekinumab | 1 | 2021 | 51 | 0.040 |
Why?
|
| Infliximab | 1 | 2021 | 159 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 244 | 0.040 |
Why?
|
| Animals | 1 | 2019 | 27512 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2007 | 2414 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2018 | 171 | 0.040 |
Why?
|
| Age Distribution | 1 | 2018 | 199 | 0.040 |
Why?
|
| Veterans | 1 | 2018 | 85 | 0.040 |
Why?
|
| Vibration | 1 | 2015 | 50 | 0.030 |
Why?
|
| Hepatitis B e Antigens | 1 | 2014 | 7 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2015 | 144 | 0.030 |
Why?
|
| Lamivudine | 1 | 2014 | 13 | 0.030 |
Why?
|
| Tenofovir | 1 | 2014 | 9 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 158 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 69 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2016 | 591 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1496 | 0.030 |
Why?
|
| Organophosphonates | 1 | 2014 | 52 | 0.030 |
Why?
|
| Adenine | 1 | 2014 | 88 | 0.030 |
Why?
|
| Guanine | 1 | 2014 | 207 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 384 | 0.030 |
Why?
|
| Biopsy | 1 | 2015 | 1184 | 0.020 |
Why?
|